Researchers review progress of treating glutamate signalling in depression
Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy. Ketamine, which has been repurposed as a rapidly acting antidepressant, ...
Mar 17, 2017
1
47